Norwegian version of this page

Preventive strategies for HPV-related disease

The project is aimed at optimizing resource-use within preventive health services for HPV-related disease, while simultaneously ensuring that these strategies continue to maximize health by reducing morbidity and mortality.


Analyses will include evaluations of forthcoming HPV-vaccines. Photo: wikipedia

About the project

We will perform registry-based analyses as well as decision-analytic modeling to assess the health and economic consequences of primary and secondary prevention strategies for HPV-related conditions in Norway and the United States.

Analyses will evaluate forthcoming HPV-vaccines, cervical and anal cancer screening approaches, and estimate the total economic burden of HPV-related diseases in Norway. The project will also assess targeted interventions that seek to reduce disparities in health.


  1. Aid priority-setting in the delivery of healthcare services that will reduce the incidence, morbidity and mortality associated with HPV-related conditions across both genders.
  2. Reduce disparity and implement the primary objective ensuring efficient use of resources.



HPV-related cancers constitute a severe group of diseases as between one- to two-thirds of those diagnosed will not survive. There is a need to develop more effective and cost-effective disease-prevention policies. Furthermore, the importance of patient involvement in the clinical decision-making process has recently been announced as a Norwegian health policy objective, necessitating the need to develop tailored interventions.

No single clinical trial can capture all the short and long term health and cost consequences of all possible strategies needed to inform complex policy decisions surrounding the prevention of HPV-related conditions. Through mathematical modeling, the proposed analyses have the potential to aid in the assessment of complex services and comparison of programs for more efficient allocation of scarce healthcare resources. By synthesizing and integrating the best available data, the use of comprehensive disease models within a decision-analytic framework can incorporate these factors, synthesize data from multiple sources, extrapolate data beyond the time horizon of single studies, reflect parameter and process uncertainty, and identify those most influential on outcomes.


  1. Quantifying the economic burden and estimating the impact of the second-generation HPV vaccine for the primary prevention of multiple HPV-related conditions.
  2. Evaluating characteristics of cervical cancer screening participants in order to improve the equitable distribution of attendance rates and assist clinical practice by better risk communication and patient-oriented diagnostic work-up.
  3. Determining whether primary screening for anal cancer among high-risk groups using novel diagnostics is warranted, with respect to the intervention’s effectiveness and costs.


  • The Norwegian Research Council


Start and finish

2014 - 2018

Tags: USA
Published Jan. 6, 2015 11:42 AM - Last modified Feb. 26, 2018 9:22 AM


Project leader Eline Aas


Detailed list of participants